EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access

Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation

H Pizzo iD, A Barbera iD, K Westreich iD, M E Seifert iD, J Mirocha iD, K Kirshner, D Puliyanda iD

Pediatric Transplantation · 2026

DOI: 10.1111/petr.70424 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Transplantation, 2026. Verfasst von H Pizzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Nephrology, Cedars-Sinai Guerin Children's, Los Angeles, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Alemtuzumab, Immunosuppressive Agents, Graft Rejection. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: LL Foundation for Youth.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alemtuzumab is an induction immunosuppressive agent effective in preventing hyperacute rejection; however, it can result in prolonged lymphocyte depletion. Here we assessed the dosing, tolerability, and outcomes with alemtuzumab induction via IV vs. SQ route in pediatric kidney transplantation.

Methods

A multicenter analysis of 119 patients < 21 years old who received alemtuzumab induction immunosuppression. Total dose (mg) and dose by body weight (mg/kg) were assessed. Tolerability was defined by the development of leukopenia (WBC < 3.0 × 10 3 /uL) or neutropenia (ANC < 1.5 × 10 3 /uL). Outcomes in the first year post‐transplant were defined by eGFR, hospitalizations, infections, development of de novo DSA, and rejection.

Results

A total of 83 and 36 recipients received alemtuzumab IV and SQ, respectively. SQ group was slightly older, 14.0 y. (SD 5.5) vs. 11.9 y. (SD 6.1) ( p = 0.07), and had more highly sensitized recipients, 14 (38.9%) vs. 10 (12.1%) ( p = 0.002). Total dose and dose by weight were higher in the SQ group, 22.3 mg (SD 8.9) vs. 14.9 mg (SD 9.5), and 0.57 mg/kg (SD 0.21) vs. 0.36 mg/kg (SD 0.18 mg), respectively ( p = 0.0001 and p < 0.0001). SQ group experienced more leukopenia and resultant medication dose reduction; however, there were no differences between the groups in eGFR, infections, hospitalizations, and rejection in the year following transplant.

Conclusion

Despite the higher dose of alemtuzumab and rates of leukopenia in the SQ group, there were no other differences in tolerability and outcomes compared to IV alemtuzumab. Overall, alemtuzumab is well tolerated during the first year post‐transplant as an induction immunosuppression agent in the pediatric population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAlemtuzumabImmunosuppressive AgentsGraft RejectionHumansFemaleChildMaleAdolescentChild, PreschoolInjections, SubcutaneousTreatment OutcomeRetrospective StudiesYoung AdultAdministration, IntravenousGraft SurvivalLeukopenia

Stichwörter der Autor:innen

immunosuppressioninductionoutcomespediatric

Substanzen

AlemtuzumabImmunosuppressive Agents

Autor:innen und Institutionen

  • Pediatric Nephrology, Cedars-Sinai Guerin Children's, Los Angeles, USA.
  • Pediatric Nephrology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, USA.
  • Pediatric Nephrology, University of North Carolina, Chapel Hill, USA.
  • Biostatistics Core, Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA.

ORCID-Profile: H Pizzo, A Barbera, K Westreich, M E Seifert, J Mirocha, D Puliyanda

Förderung

  • LL Foundation for Youth

Zitieren

APA

Pizzo, H., Barbera, A., Westreich, K., Seifert, M. E., Mirocha, J., Kirshner, K., & Puliyanda, D. (2026). Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.70424

Vancouver

Pizzo H, Barbera A, Westreich K, Seifert ME, Mirocha J, Kirshner K, et al. Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation. Pediatric Transplantation. 2026. doi:10.1111/petr.70424

BibTeX
@article{Pizzo2026,
  author = {Pizzo, H and Barbera, A and Westreich, K and Seifert, M E and Mirocha, J and Kirshner, K and Puliyanda, D},
  title = {Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation},
  journal = {Pediatric Transplantation},
  year = {2026},
  doi = {10.1111/petr.70424}
}
Kostenlos starten →